Role of cyclooxygenase-2 in gastric cancer development and progression

World Journal of Gastroenterology

Volumn 19, Issue 42, 2013, Pages 7361-7368

  Cheng, Jian ^a   Fan, Xiao Ming ^a  

^a JINSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Carcinogenesis; Cyclooxygenase 2; Gastric cancer; Molecular mechanism; Prostagladin

Indexed keywords

CYCLOOXYGENASE 2; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; TUMOR NECROSIS FACTOR; VASCULOTROPIN C;

APOPTOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CELL PROLIFERATION; GENE MUTATION; HELICOBACTER INFECTION; HUMAN; IMMUNOSURVEILLANCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; STOMACH CANCER; SURVIVAL RATE; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR MICROENVIRONMENT; UPREGULATION;

CARCINOGENESIS; CYCLOOXYGENASE-2; GASTRIC CANCER; MOLECULAR MECHANISM; PROSTAGLADIN;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; DISEASE PROGRESSION; HUMANS; INCIDENCE; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887587260     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i42.7361     Document Type: Review

References (100)

1. Bornschein J, Rokkas T, Selgrad M, Malfertheiner P. Gastric cancer: clinical aspects, epidemiology and molecular background. Helicobacter 2011; 16 Suppl 1: 45-52 [PMID: 21896085 DOI: 10.1111/j.1523-5378.2011.00880.x]
2. Jing JJ, Liu HY, Hao JK, Wang LN, Wang YP, Sun LH, Yuan Y. Gastric cancer incidence and mortality in Zhuanghe, China, between 2005 and 2010. World J Gastroenterol 2012; 18: 1262-1269 [PMID: 22468091 DOI: 10.3748/wjg.v18.i11.1262]
3. Krejs GJ. Gastric cancer: epidemiology and risk factors. Dig Dis 2010; 28: 600-603 [PMID: 21088409 DOI: 10.1159/000320277]
4. Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, Inoue M. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol 2011; 17: 4421-4428 [PMID: 22110269 DOI: 10.3748/wjg.v17.i39.4421]
5. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid Res 2009; 50 Suppl: S423-S428 [PMID: 19095631 DOI: 10.1194/jlr.R800094- JLR200]
6. Yu Q, Purwaha P, Ni K, Sun C, Mallik S, Qian SY. Characterization of novel radicals from COX-catalyzed arachidonic acid peroxidation. Free Radic Biol Med 2009; 47: 568-576 [PMID: 19482075 DOI: 10.1016/j.freeradbiomed.2009]
7. Ruan YC, Zhou W, Chan HC. Regulation of smooth muscle contraction by the epithelium: role of prostaglandins. Physiology (Bethesda) 2011; 26: 156-170 [PMID: 21670162 DOI: 10.1152/physiol.00036.2010]
8. Hein AM, O'Banion MK. Neuroinflammation and memory: the role of prostaglandins. Mol Neurobiol 2009; 40: 15-32 [PMID: 19365736 DOI: 10.1007/s12035-009-8066-z]
9. Stratton R, Shiwen X. Role of prostaglandins in fibroblast activation and fibrosis. J Cell Commun Signal 2010; 4: 75-77 [PMID: 20531982 DOI: 10.1007/s12079-010-0089-8]
10. Gibb W. The role of prostaglandins in human parturition. Ann Med 1998; 30: 235-241 [PMID: 9677008 DOI: 10.3109/07 853899809005850]
11. Wang D, Mann JR, DuBois RN. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 2005; 128: 1445-1461 [PMID: 15887126 DOI: 10.1053/ j.gastro.2004.09.080]
12. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23: 2840-2855 [PMID: 15837998 DOI: 10.1200/jco.2005.09.051]
13. Hogendorf P, Durczyński A, Kumor A, Strzelczyk J. Prostaglandin E2 (PGE2) in portal blood in patients with pancreatic tumor--a single institution series. J Invest Surg 2012; 25: 8-13 [PMID: 22272632 DOI: 10.3109/08941939.2011.592569]
14. Li J, Feng G, Liu J, Rong R, Luo F, Guo L, Zhu T, Wang G, Chu Y. Renal cell carcinoma may evade the immune system by converting CD4+Foxp3- T cells into CD4+CD25+Foxp3+ regulatory T cells: Role of tumor COX-2-derived PGE2. Mol Med Rep 2010; 3: 959-963 [PMID: 21472340 DOI: 10.3892/ mmr.2010.374]
15. Davidge ST. Prostaglandin H synthase and vascular function. Circ Res 2001; 89: 650-660 [PMID: 11597987 DOI: 10.1161/hh2001.098351]
16. Bamba H, Ota S, Arai S, Ban S, Shimizu M, Imai Y, Kawamoto C, Yoshida Y, Fujiwara K. Expression of cyclooxygenase- 2 in human hyperplastic gastric polyps. J Exp Clin Cancer Res 2003; 22: 425-430 [PMID: 14582702]
17. Peskar BM, Sawka N, Ehrlich K, Peskar BA. Role of cyclooxygenase- 1 and -2, phospholipase C, and protein kinase C in prostaglandin-mediated gastroprotection. J Pharmacol Exp Ther 2003; 305: 1233-1238 [PMID: 12626649 DOI: 10.1124/ jpet.103.049650]
18. Tokuyama H, Hayashi K, Matsuda H, Kubota E, Honda M, Okubo K, Ozawa Y, Saruta T. Distinct role of intrarenal cyclooxygenase-1/2 in chronic unilateral renal ischemia. Nephron 2002; 92: 183-191 [PMID: 12187101 DOI: 10.1159/000064479]
19. Lipsky PE. Role of cyclooxygenase-1 and -2 in health and disease. Am J Orthop (Belle Mead NJ) 1999; 28: 8-12 [PMID: 10193997]
20. Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, Haglund C, Van Lanschot JJ, Offerhaus GJ, Ristimaki A. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 2003; 111: 915-925 [PMID: 14616542 DOI: 10.1034/ j.1600-0463.2003.1111001.x]
21. Sonoda R, Naomoto Y, Shirakawa Y, Fujiwara Y, Yamatsuji T, Noma K, Tanabe S, Takaoka M, Gunduz M, Tsujigiwa H, Nagatsuka H, Ohara N, Yoshino T, Takubo K, Vieth M, Tanaka N. Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma. Histopathology 2010; 57: 90-100 [PMID: 20653782 DOI: 10.1111/ j.1365-2559.2010.03594.x]
22. Yao L, Liu F, Hong L, Sun L, Liang S, Wu K, Fan D. The function and mechanism of COX-2 in angiogenesis of gastric cancer cells. J Exp Clin Cancer Res 2011; 30: 13 [PMID: 21266034 DOI: 10.1186/1756-9966-30-13]
23. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-1280 [PMID: 9102213]
24. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, Evans J, O'Neill G. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996; 111: 445-454 [PMID: 8690211 DOI: 10.1053/gast.1996.v111. pm8690211]
25. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044 [PMID: 16404738 DOI: 10.1002/ijc.21731]
26. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899 [PMID: 20303878 DOI: 10.1016/j.cell.2010.01.025]
27. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010; 29: 781-788 [PMID: 19946329 DOI: 10.1038/onc.2009.421]
28. de Heer P, Gosens MJ, de Bruin EC, Dekker-Ensink NG, Putter H, Marijnen CA, van den Brule AJ, van Krieken JH, Rutten HJ, Kuppen PJ, van de Velde CJ. Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy. Clin Cancer Res 2007; 13: 2955-2960 [PMID: 17504996 DOI: 10.1158/1078-0]
29. Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000; 86: 667-671 [PMID: 10797288 DOI: 10.1002/(sici)1097-0215(20000601)86:5]
30. Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta K. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 2007; 97: 1523-1531 [PMID: 17971769 DOI: 10.1038/sj.bjc.6604057]
31. Uefuji K, Ichikura T, Mochizuki H, Shinomiya N. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncol 1998; 69: 168-172 [PMID: 9846504 DOI: 10.1002/ (SICI)1096-9098(199811)]
32. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, Kim HS, Nam DK, Lee KB, Kim HC. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000; 6: 519-525 [PMID: 10690533]
33. Mao XY, Wang XG, Lv XJ, Xu L, Han CB. COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarray. World J Gastroenterol 2007; 13: 3466-3471 [PMID: 17659693]
34. Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, Shiozaki H, Hori M. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999; 94: 451-455 [PMID: 10022645 DOI: 10.1111/j.1572-0241.1999.876_e.x]
35. Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, Nordling S, Ristimäki A, Haglund C. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res 2005; 11: 7362-7368 [PMID: 16243808 DOI: 10.1158/1078-0432.ccr-05-0764]
36. Yu HG, Li JY, Yang YN, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F. Increased abundance of cyclooxygenase-2 correlates with vascular endothelial growth factor-A abundance and tumor angiogenesis in gastric cancer. Cancer Lett 2003; 195: 43-51 [PMID: 12767510 DOI: 10.1016/S0304-3835(03)00153-8]
37. Da MX, Wu XT, Wang J, Guo TK, Zhao ZG, Luo T, Zhang MM, Qian K. Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res 2008; 39: 92-99 [PMID: 18068001 DOI: 10.1016/ j.arcmed.2007.06.021]
38. Li M, Liu W, Zhu YF, Chen YL, Zhang BZ, Wang R. Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer. Acta Oncol 2006; 45: 1115-1119 [PMID: 17118848 DOI: 10.1088/02841860601043066]
39. Al-Moundhri MS, Al-Hadabi I, Al-Mawaly K, Kumar S, Al-Lawati FA, Bhatnager G, Kuruvila S, Al-Hamdani A, El-Sayed SM, Al-Bahrani B. Prognostic significance of cyclooxygenase- 2, epidermal growth factor receptor 1, and microvascular density in gastric cancer. Med Oncol 2012; 29: 1739-1747 [PMID: 22048943 DOI: 10.1007/s12032-011-0098-3]
40. Oba M, Miwa K, Fujimura T, Harada S, Sasaki S, Hattori T. Chemoprevention of glandular stomach carcinogenesis through duodenogastric reflux in rats by a COX-2 inhibitor. Int J Cancer 2008; 123: 1491-1498 [PMID: 18646190 DOI: 10.1002/ijc.23742]
41. van Rees BP, Saukkonen K, Ristimäki A, Polkowski W, Tytgat GN, Drillenburg P, Offerhaus GJ. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002; 196: 171-179 [PMID: 11793368 DOI: 10.1002/ path.1033]
42. Joo YE, Oh WT, Rew JS, Park CS, Choi SK, Kim SJ. Cyclooxygenase- 2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion 2002; 66: 222-229 [PMID: 12592098 DOI: 10.1159/000068366]
43. Han SL, Tang HJ, Hua YW, Ji SQ, Lin DX. Expression of COX-2 in stomach cancers and its relation to their biological features. Dig Surg 2003; 20: 107-114 [PMID: 12686777 DOI: 10.1159/000069384]
44. Fanelli MF, Chinen LT, Begnami MD, Costa WL, Fregnami JH, Soares FA, Montagnini AL. The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology 2012; 61: 153-161 [PMID: 22582975 DOI: 10.1111/j.1365-2559.2011.04139.x]
45. Mrena J, Wiksten JP, Kokkola A, Nordling S, Ristimäki A, Haglund C. COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol 2010; 31: 1-7 [PMID: 20237896 DOI: 10.1007/s13277-009-0001-4]
46. Zhang LJ, Wang SY, Huo XH, Zhu ZL, Chu JK, Ma JC, Cui DS, Gu P, Zhao ZR, Wang MW, Yu J. Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions. World J Gastroenterol 2009; 15: 2731-2738 [PMID: 19522023 DOI: 10.3748/wjg.15.2731]
47. Pero R, Peluso S, Angrisano T, Tuccillo C, Sacchetti S, Keller S, Tomaiuolo R, Bruni CB, Lembo F, Chiariotti L. Chromatin and DNA methylation dynamics of Helicobacter pyloriinduced COX-2 activation. Int J Med Microbiol 2011; 301: 140-149 [PMID: 20934379 DOI: 10.1016/j.ijmm.2010.06.009]
48. Targosz A, Brzozowski T, Pierzchalski P, Szczyrk U, Ptak- Belowska A, Konturek SJ, Pawlik W. Helicobacter pylori promotes apoptosis, activates cyclooxygenase (COX)-2 and inhibits heat shock protein HSP70 in gastric cancer epithelial cells. Inflamm Res 2012; 61: 955-966 [PMID: 22610150 DOI: 10.1007/s00011-012-0487-x]
49. Asaka M. Helicobacter pylori infection and gastric cancer. Intern Med 2002; 41: 1-6 [PMID: 11838583 DOI: 10.2169/internalmedicine. 41.1]
50. Fu S, Ramanujam KS, Wong A, Fantry GT, Drachenberg CB, James SP, Meltzer SJ, Wilson KT. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999; 116: 1319-1329 [PMID: 10348815 DOI: 10.1016/ S0016-5085(99)70496-8]
51. Xiao F, Furuta T, Takashima M, Shirai N, Hanai H. Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by Helicobacter pylori infection in C57BL/6 mice. Aliment Pharmacol Ther 2001; 15: 875-886 [PMID: 11380326 DOI: 10.1046/j.1365-2036.2001.00965.x]
52. Romano M, Ricci V, Memoli A, Tuccillo C, Di Popolo A, Sommi P, Acquaviva AM, Del Vecchio Blanco C, Bruni CB, Zarrilli R. Helicobacter pylori up-regulates cyclooxygenase- 2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J Biol Chem 1998; 273: 28560-28563 [PMID: 9786845 DOI: 10.1074/jbc.273.44.28560]
53. Cho SO, Lim JW, Kim KH, Kim H. Involvement of Ras and AP-1 in Helicobacter pylori-induced expression of COX-2 and iNOS in gastric epithelial AGS cells. Dig Dis Sci 2010; 55: 988-996 [PMID: 19495976 DOI: 10.1007/s10620-009- 0828-y]
54. Tokudome S, Ghadimi R, Suzuki S, Hosono A, Tanaka T, Arakawa K, Zhao Y, Hattori N, Agawa H, Marumoto M, Ando R, Moore MA. Helicobacter pylori infection appears the prime risk factor for stomach cancer. Int J Cancer 2006; 119: 2991; author reply 2992 [PMID: 17016826 DOI: 10.1002/ ijc.22223]
55. Walduck AK, Weber M, Wunder C, Juettner S, Stolte M, Vieth M, Wiedenmann B, Meyer TF, Naumann M, Hoecker M. Identification of novel cyclooxygenase-2-dependent genes in Helicobacter pylori infection in vivo. Mol Cancer 2009; 8: 22 [PMID: 19317916 DOI: 10.1186/1476-4598-8-22]
56. Li Q, Liu N, Shen B, Zhou L, Wang Y, Wang Y, Sun J, Fan Z, Liu RH. Helicobacter pylori enhances cyclooxygenase 2 expression via p38MAPK/ATF-2 signaling pathway in MKN45 cells. Cancer Lett 2009; 278: 97-103 [PMID: 19201083 DOI: 10.1016/j.canlet.2008.12.032]
57. Subramaniam D, Ramalingam S, May R, Dieckgraefe BK, Berg DE, Pothoulakis C, Houchen CW, Wang TC, Anant S. Gastrin-mediated interleukin-8 and cyclooxygenase-2 gene expression: differential transcriptional and posttranscriptional mechanisms. Gastroenterology 2008; 134: 1070-1082 [PMID: 18395088 DOI: 10.1053/j.gastro.2008.01.040]
58. Hohla F, Schally AV, Kanashiro CA, Buchholz S, Baker B, Kannadka C, Moder A, Aigner E, Datz C, Halmos G. Growth inhibition of non-small-cell lung carcinoma by BN/ GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt. Proc Natl Acad Sci USA 2007; 104: 18671-18676 [PMID: 18003891 DOI: 10.1073/pnas.0709455104]
59. Saukkonen K, Nieminen O, van Rees B, Vilkki S, Härkönen M, Juhola M, Mecklin JP, Sipponen P, Ristimäki A. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001; 7: 1923-1931 [PMID: 11448905]
60. Hermanova M, Trna J, Nenutil R, Dite P, Kala Z. Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions. Eur J Gastroenterol Hepatol 2008; 20: 732-739 [PMID: 18617777 DOI: 10.1097/MEG.0b013e3282f945fb]
61. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J. Retinoblastoma-protein-dependent cellcycle inhibition by the tumour suppressor p16. Nature 1995; 375: 503-506 [PMID: 7777060 DOI: 10.1038/375503a0]
62. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707 [PMID: 8259215 DOI: 10.1038/366704a0]
63. Goto T, Mizukami H, Shirahata A, Yokomizo K, Kitamura YH, Sakuraba K, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K. Methylation of the p16 gene is frequently detected in lymphatic-invasive gastric cancer. Anticancer Res 2010; 30: 2701-2703 [PMID: 20683001]
64. Kobayashi N, Toyooka S, Yanai H, Soh J, Fujimoto N, Yamamoto H, Ichihara S, Kimura K, Ichimura K, Sano Y, Kishimoto T, Date H. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer 2008; 62: 120-125 [PMID: 18395929 DOI: 10.1016/ j.lungcan.2008.02.013]
65. Li Q, Gao SL, Cui LJ, Li MQ. Expression of COX-2 and P16 protein and their correlations in various types of gastric polyps and gastric cancer cell. Shijie Huaren Xiaohua Zazhi 2005; 13: 2506-2509 [DOI: 10.3969/j.issn.1009-3079.2005.20.025]
66. Zhai JS, Li N, Zhang L, Wang YM, Zhu CH, Wu K. Expression of P16,C-MYC and COX-2 in Gastric Carcinoma and Relationship with the Prognosis of Patients. Zhejiang Zhongyiyao Daxue Xuebao 2009; 33: 321-322 [DOI: 10.3969/j.issn.1 005-5509.2009.03.012]
67. Oshima H, Oshima M. The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol 2012; 47: 97-106 [PMID: 22218775 DOI: 10.1007/s00535-011-0523-6]
68. Lim JW, Kim H, Kim KH. NF-kappaB, inducible nitric oxide synthase and apoptosis by Helicobacter pylori infection. Free Radic Biol Med 2001; 31: 355-366 [PMID: 11461773 DOI: 10.1016/S0891-5849(01)00592-5]
69. Xu CX, Jin H, Chung YS, Shin JY, Lee KH, Beck GR, Palmos GN, Choi BD, Cho MH. Chondroitin sulfate extracted from ascidian tunic inhibits phorbol ester-induced expression of Inflammatory factors VCAM-1 and COX-2 by blocking NFkappaB activation in mouse skin. J Agric Food Chem 2008; 56: 9667-9675 [PMID: 18800802 DOI: 10.1021/jf801578]
70. Li YS, Wu LP, Li KH, Liu YP, Xiang R, Zhang SB, Zhu LY, Zhang LY. Involvement of nuclear factor κB (NF-κB) in the downregulation of cyclooxygenase-2 (COX-2) by genistein in gastric cancer cells. J Int Med Res 2011; 39: 2141-2150 [PMID: 22289529 DOI: 10.1177/147323001103900610]
71. Nam SY, Ko YS, Jung J, Yoon J, Kim YH, Choi YJ, Park JW, Chang MS, Kim WH, Lee BL. A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor- κB promotes gastric tumour growth and angiogenesis. Br J Cancer 2011; 104: 166-174 [PMID: 21119667 DOI: 10.1038/ sj.bjc.6606020]
72. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867 [PMID: 12490959 DOI: 10.1038/nature01322]
73. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444 [PMID: 18650914 DOI: 10.1038/nature07205]
74. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-466 [PMID: 15329734 DOI: 10.1038/nature02924]
75. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-296 [PMID: 15294155 DOI: 10.1016/ j.cell.2004.07.013]
76. Akhtar M, Cheng Y, Magno RM, Ashktorab H, Smoot DT, Meltzer SJ, Wilson KT. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res 2001; 61: 2399-2403 [PMID: 11289104]
77. Moalic S, Liagre B, Le Bail JC, Beneytout JL. Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor. Int J Oncol 2001; 18: 533-540 [PMID: 11179483]
78. Enders GA. Cyclooxygenase-2 overexpression abrogates the antiproliferative effects of TGF-beta. Br J Cancer 2007; 97: 1388-1392 [PMID: 17955050 DOI: 10.1038/sj.bjc.6604048]
79. Fu YG, Sung JJ, Wu KC, Wu HP, Yu J, Chan M, Chan VY, Chan KK, Fan DM, Leung WK. Inhibition of gastric cancerassociated angiogenesis by antisense COX-2 transfectants. Cancer Lett 2005; 224: 243-252 [PMID: 15914275 DOI: 10.1016/j.canlet.2004.11.038]
80. Sun WH, Zhu F, Chen GS, Su H, Luo C, Zhao QS, Zhang Y, Shao Y, Sun J, Zhou SM, Ding GX, Cheng YL. Blockade of cholecystokinin-2 receptor and cyclooxygenase-2 synergistically induces cell apoptosis, and inhibits the proliferation of human gastric cancer cells in vitro. Cancer Lett 2008; 263: 302-311 [PMID: 18258354 DOI: 10.1016/j.canlet.2008.01.012]
81. Chen XL, Su BS, Sun RQ, Zhang J, Wang YL. Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma. World J Gastroenterol 2005; 11: 1228-1231 [PMID: 15754411]
82. Han JA, Kim JI, Ongusaha PP, Hwang DH, Ballou LR, Mahale A, Aaronson SA, Lee SW. P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J 2002; 21: 5635-5644 [PMID: 12411481 DOI: 10.1093/emboj/cdf591]
83. Casado M, Mollá B, Roy R, Fernández-Martínez A, Cucarella C, Mayoral R, Boscá L, Martín-Sanz P. Protection against Fas-induced liver apoptosis in transgenic mice expressing cyclooxygenase 2 in hepatocytes. Hepatology 2007; 45: 631-638 [PMID: 17326157 DOI: 10.1002/hep.21556]
84. Bamba H, Ota S, Kato A, Kawamoto C, Fujiwara K. Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. Biochem Biophys Res Commun 2000; 273: 485-491 [PMID: 10873632 DOI: 10.1006/bbrc.2000.2969]
85. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000; 6: 135-138 [PMID: 10656441]
86. Vidal O, Soriano-Izquierdo A, Pera M, Elizalde JI, Palacín A, Castells A, Piqué JM, Volant A, Metges JP. Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg 2008; 12: 1005-1014 [PMID: 17972143 DOI: 10.1007/ s11605-007-0336-3]
87. Kim N, Kim CH, Ahn DW, Lee KS, Cho SJ, Park JH, Lee MK, Kim JS, Jung HC, Song IS. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. J Gastroenterol Hepatol 2009; 24: 480-487 [PMID: 18823436 DOI: 10.1111/j.1440-1746.2008.05599.x]
88. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier- Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001; 85: 273-278 [PMID: 11461089 DOI: 10.1054/bjoc.2001.1876]
89. Gou HF, Chen XC, Zhu J, Jiang M, Yang Y, Cao D, Hou M. Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res 2011; 30: 14 [PMID: 21272377 DOI: 10.1186/1756-9966-30-14]
90. Rao DS, Gui D, Koski ME, Popoviciu LM, Wang H, Reiter RE, Said JW. An inverse relation between COX-2 and E-cadherin expression correlates with aggressive histologic features in prostate cancer. Appl Immunohistochem Mol Morphol 2006; 14: 375-383 [PMID: 17122632 DOI: 10.1097/01. pai.0000210417.61117.6c]
91. Dicken BJ, Graham K, Hamilton SM, Andrews S, Lai R, Listgarten J, Jhangri GS, Saunders LD, Damaraju S, Cass C. Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann Surg 2006; 243: 64-73 [PMID: 16371738 DOI: 10.1097/01.sla.0000194087.96582.3e]
92. Zhao Y, Zhou S, Heng CK. Celecoxib inhibits serum amyloid a-induced matrix metalloproteinase-10 expression in human endothelial cells. J Vasc Res 2009; 46: 64-72 [PMID: 18552508 DOI: 10.1159/000139134]
93. Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, Baba H, Saya H, Nagano O. CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci 2010; 101: 673-678 [PMID: 20028388 DOI: 10.1111/ j.1349-7006.2009.01430.x]
94. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S, Dubinett SM. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase- 2-dependent invasion. J Biol Chem 2002; 277: 50828-50833 [PMID: 12393872 DOI: 10.1074/jbc.M210707200]
95. Jia XQ, Zhong N, Han LH, Wang JH, Yan M, Meng FL, Zhang SZ. Effect of NS-398 on colon cancer cells. World J Gastroenterol 2005; 11: 353-356 [PMID: 15637743]
96. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, Saya H. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011; 19: 387-400 [PMID: 21397861 DOI: 10.1016/j.ccr.2011.01.038]
97. Shin VY, Wu WK, Chu KM, Wong HP, Lam EK, Tai EK, Koo MW, Cho CH. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Mol Cancer Res 2005; 3: 607-615 [PMID: 16317086 DOI: 10.1158/1541-7786.mcr-05-0106]
98. Yuan XL, Chen L, Li MX, Dong P, Xue J, Wang J, Zhang TT, Wang XA, Zhang FM, Ge HL, Shen LS, Xu D. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin Immunol 2010; 134: 277-288 [PMID: 19900843 DOI: 10.1016/j.clim.2009.10.005]
99. Ahmadi M, Emery DC, Morgan DJ. Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res 2008; 68: 7520-7529 [PMID: 18794140 DOI: 10.1158/0008-5472.can-08-1060]
100. Chen TH, Fukuhara K, Mandai M, Matsumura N, Kariya M, Takakura K, Fujii S. Increased cyclooxygenase-2 expression is correlated with suppressed antitumor immunity in cervical adenocarcinomas. Int J Gynecol Cancer 2006; 16: 772-779 [PMID: 16681759 DOI: 10.1111/j.1525-1438.2006.00385.x]